Blue sharks might actually be some of nature's most unexpected chameleons
Blue sharks have become very well known for the color of their skin, but new research indicates that these iconic sharks might be more than meets the eye. In fact, blue sharks might just be one of nature's best chameleons, as new data suggests the components responsible for the shark's coloring could allow it to change colors based on its environment.
The research comes from a group of marine biologists who shared their findings at the most recent Society for Experimental Biology Annual Conference in Belgium. The researchers say they discovered these findings while more closely inspecting the small tooth-like scales that are responsible for the blue coloring of the sharks.
Today's Top Deals
XGIMI Prime Day deals feature the new MoGo 4 and up to 42% off smart projectors
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
These tooth-like scales are known as dermal denticles. When looking at them more closely, the researchers found that the scales feature small pulp cavities that contain guanine crystals. These crystals are responsible for the camouflage ability found in chameleons, which suggests that blue sharks may be able to use similar color-changing abilities to hide in different environments.
The belief is that these color-changing crystals allow the sharks to blend in with the darker waters of the deep. For example, the researchers suggest that the cells could become more tightly packed together as the pressure increases on the shark's body, thus making the creature's skin much darker when it dives deeper.
So far, the researchers have only simulated the possible chances of what might happen when the pressure is increased on the cells. From here, the researchers want to take their findings and try to translate them to the real world by investigating the blue shark's chameleon ability in greater depth. The hope is that they'll be able to prove that the sharks change their color based on their environment, even if that just means they get darker when diving deeper.
There's a lot we still don't know about sharks, including why some sharks freeze when turned upside down. But, hopefully, future research like this can help us uncover more about these majestic and terrifying creatures.
More Top Deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
See the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
15 minutes ago
- Forbes
See The Perseid Meteor Shower Now Before It Peaks, Experts Say
A falling star crosses the night sky over Halle / Saale, eastern Germany, during the peak in ... More activity of the annual Perseids meteor shower on August 13, 2015. (Credit: HENDRIK SCHMIDT/AFP/Getty Images) The annual Perseid meteor shower is a highlight of the astronomical calendar. Its peak is still a few weeks away, but it began earlier this week — and so did a slew of poorly researched articles advising when to watch it. What almost no one else seems to realize is that this year, the normally prolific Perseids will generally disappoint because the peak rates of 'shooting stars' on Aug. 12-13 will occur in a night sky bleached by a near-full moon. Happily, all is not lost. Here's how and when to watch the Perseid meteor shower in 2025 — including what experts think is the best time to get a glimpse of it, despite the harsh sky conditions. The Problem With The Perseid Meteor Shower In 2025 The Perseids can produce about 75 'shooting stars' per hour on its peak night, but only in a dark sky. This year, under clear, dark skies with a wide-open view, observers might spot far fewer. 'I'd expect a typical person with a clear view of the full sky to be able to see somewhere in the ballpark of five to 10 meteors per hour during the night of August 12-13,' said Dr. Qicheng Zhang, astronomer at Lowell Observatory in Flagstaff, Arizona, in an email. That's how huge impact of a bright gibbous moon is. It will be about 84%-lit and rise just as it starts to get dark. Why You Shouldn't Wait For The Perseid To Peak Although Aug. 12-13 is the peak night, meteors may be more easily visible on nights both before and after, when sky conditions are better. For example, this Thursday there's a New Moon, which occurs when our natural satellite is roughly between the Earth and the sun. That means it's invisible, leaving the night skies dark all night all of this week. Anytime after dark this week is therefore a great opportunity for viewing the Perseid meteor shower — especially with the Southern Delta Aquariid meteor shower peaking on July 29/30 — though expect rates of 'shooting stars' to be relatively low. 'A few meteors might be visible in the early morning on the first couple of days [of August]How And Where To See 'Shooting Stars' The advice for meteor showers is simple — get far from light pollution. If you intend to go looking for Perseids this week, or after the peak has passed, seeking out dark skies is essential. Aim for a wide, open space with minimal haze and obstructions to catch as many meteors as possible. However, for the peak night on Aug. 12-13 for the Perseids this year, that's not helpful advice. Even if you get as far from artificial lighting as possible on that peak night, you'll still find yourself under a sky similar to that of a city. Why You Need To Be Patient Seeing a meteor shower successfully means being patient. It also means not looking at a smartphone, whose white light instantly kills night vision. Add the worsening problem of light pollution, and it's easy to see why almost nobody ever sees 'shooting stars' these days. 'As with most annual meteor showers, observing meteors takes a lot of patience, and it may take watching for an hour or more to see a handful of meteors,' said Zhang. Also, any strong and sudden outbursts in meteor activity — which are hard to predict, but possible — may last only a few hours. "Because they're unpredictable in time, they require either a lot of luck or watching for many hours to have a reasonable chance of catching,' said Zhang. Wishing you clear skies and wide eyes.
Associated Press
41 minutes ago
- Associated Press
EUMETSAT Takes Control of Europe's First Geostationary Sounder Satellite
DARMSTADT, Germany--(BUSINESS WIRE)--Jul 21, 2025-- After more than two weeks of complex manoeuvring, precise positioning and meticulous checks, EUMETSAT assumed control of the Meteosat Third Generation Sounder 1 (MTG-S1) spacecraft on 18 July 2025, the latest addition to its fleet of geostationary meteorological satellites. This press release features multimedia. View the full release here: MTG-S1 in orbit Following MTG-S1's successful launch on 1 July 2025, the satellite, which carries the Infrared Sounder (IRS) and the European Union's Copernicus Sentinel-4 mission, has completed its launch and early operations phase (LEOP) and is now in orbit around 36,000km above the Equator at 3.4°W longitude. MTG-S1 will now begin months of intensive testing by experts at EUMETSAT with partners from the European Space Agency (ESA) and in industry to prepare for the delivery of vital data and products to specialists across EUMETSAT member states and beyond. Once fully commissioned, the satellite will deliver entirely new streams of atmospheric sounding data, enabling national meteorological services to deliver earlier and more accurate warnings that will save lives and protect property and infrastructure. 'The successful completion of the LEOP confirms that the MTG-S1 satellite platform is functioning as expected and ready for the next stage,' said Julia Hunter-Anderson, EUMETSAT's Meteosat Third Generation LEOP Manager. 'Taking control of the satellite in a healthy condition marks a major milestone for EUMETSAT and our partners. This achievement is the culmination of the immense dedication and hard work of hundreds of people over many years. 'For EUMETSAT, it is also the beginning of another journey: together with ESA and industry to commission the satellite and prepare its remarkable instruments to deliver critical near-real-time sounding data and products. These observations will inform decision makers, help protect societies, improve lives and livelihoods, and enhance how we monitor the climate and forecast weather across our member states and beyond.' For further updates on MTG-S1, visit EUMETSAT's launch hub, which features news, interviews, and insights into the satellite's journey. Find all relevant information, biographies of speakers, videos and testimonials on our dedicated press page. About EUMETSAT EUMETSAT, Europe's meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies. For more information: EUMETSAT. View source version on CONTACT: Media Relations EUMETSAT: Tel. : +49 6151 807 7320 Email:[email protected] KEYWORD: GERMANY EUROPE INDUSTRY KEYWORD: SATELLITE SCIENCE OTHER SCIENCE RESEARCH TECHNOLOGY SOURCE: EUMETSAT Copyright Business Wire 2025. PUB: 07/21/2025 02:00 AM/DISC: 07/21/2025 02:01 AM
Yahoo
2 hours ago
- Yahoo
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeks The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified Analysis of the ALIENTO and ARNASA data will be discussed with regulatory authorities and shared at an upcoming medical meeting Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The pivotal phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualised exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction, at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified. "While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab.' Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting. About the ALIENTO and ARNASA studies1,2Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signalling of IL-33.3 The astegolimab COPD pivotal programme consists of two registrational studies, the phase IIb ALIENTO (NCT05037929) and phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multicentre studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualised rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations – inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA). [Internet; cited March 2025]. Available from: [2] A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease. [Internet; cited March 2025]. Available from: Kelsen SG, Agache O, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of Allergy and Clinical Immunology. 2021 Sep;148(3):790–8. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Media Investor Release Astegolimab ALIENTO ARNASA EnglishSign in to access your portfolio
